Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Recent Insights into Therapy Resistance in Osteosarcoma
Zachary D. Prudowsky, Jason T. Yustein
Cancers (2020) Vol. 13, Iss. 1, pp. 83-83
Open Access | Times Cited: 78

Showing 26-50 of 78 citing articles:

End-to-End Deep Learning Prediction of Neoadjuvant Chemotherapy Response in Osteosarcoma Patients Using Routine MRI
Ping Yin, Xinyu Zhang, Ying Liu, et al.
Deleted Journal (2025)
Closed Access
Multidrug-resistant osteosarcoma: A systematic review
Mokhtar Ahmed Alsayed, Raad M. M. Althaqafi, Hashem Bukhary, et al.
Journal of Clinical Sciences (2025) Vol. 22, Iss. 1, pp. 42-50
Open Access
The whole transcriptome analysis using FFPE and fresh tissue samples identifies the molecular fingerprint of osteosarcoma
B. Poudel, Sulev Kõks
Experimental Biology and Medicine (2024) Vol. 249
Open Access | Times Cited: 3
Make it STING: nanotechnological approaches for activating cGAS/STING as an immunomodulatory node in osteosarcoma
John O’Donoghue, Fiona E. Freeman
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 3
Hydroxytyrosol Prevents Doxorubicin-Induced Oxidative Stress and Apoptosis in Cardiomyocytes
Ivana Sirangelo, Maria Liccardo, Clara Iannuzzi
Antioxidants (2022) Vol. 11, Iss. 6, pp. 1087-1087
Open Access | Times Cited: 15
MiRNA-520a-3p combined with folic acid conjugated Fe2O3@PDA multifunctional nanoagents for MR imagine and antitumor gene-photothermal therapy
Xue Li, Shuang Wang, Qingzhe Gao, et al.
Nanotechnology (2023) Vol. 34, Iss. 37, pp. 375101-375101
Closed Access | Times Cited: 8
A Novel Six Metastasis-Related Prognostic Gene Signature for Patients With Osteosarcoma
Di Zheng, Kezhou Xia, Ling Yu, et al.
Frontiers in Cell and Developmental Biology (2021) Vol. 9
Open Access | Times Cited: 18
FOXO3a-dependent up-regulation of HSP90 alleviates cisplatin-induced apoptosis by activating FUNDC1-mediated mitophagy in hypoxic osteosarcoma cells
Dian Lu, Rui Liu, Yuting Zhou, et al.
Cellular Signalling (2022) Vol. 101, pp. 110500-110500
Closed Access | Times Cited: 14
Two Beats One: Osteosarcoma Therapy with Light-Activated and Chemo-Releasing Keratin Nanoformulation in a Preclinical Mouse Model
Elisa Martella, Barbara Dozza, Claudia Ferroni, et al.
Pharmaceutics (2022) Vol. 14, Iss. 3, pp. 677-677
Open Access | Times Cited: 11
Cytotoxicity Enhancement in Osteosarcoma with Multifunctional I-131 Radiotherapeutic Nanoparticles: In Vitro Three-Dimensional Spheroid Model and Release Kinetics Modeling
Suphalak Khamruang Marshall, Maneerat Taweesap, Boonyisa Saelim, et al.
Molecules (2024) Vol. 29, Iss. 3, pp. 630-630
Open Access | Times Cited: 2
Advances in prognostic models for osteosarcoma risk
Yi Yao, Dapeng Wang, Zheng Li, et al.
Heliyon (2024) Vol. 10, Iss. 7, pp. e28493-e28493
Open Access | Times Cited: 2
Repurposing the diuretic benzamil as an anti-osteosarcoma agent that acts by suppressing integrin/FAK/STAT3 signalling and compromising mitochondrial function
Meng-Chieh Lin, Guan-Yu Chen, Hsin‐Hsien Yu, et al.
Bone and Joint Research (2024) Vol. 13, Iss. 4, pp. 157-168
Open Access | Times Cited: 2
Nrf2: a key regulator in chemoradiotherapy resistance of osteosarcoma
Xianglin Peng, Jing Feng, Yang Han, et al.
Genes & Diseases (2024) Vol. 12, Iss. 4, pp. 101335-101335
Open Access | Times Cited: 2
Blocking CXCR4–CARM1–YAP axis overcomes osteosarcoma doxorubicin resistance by suppressing aerobic glycolysis
Zihua Li, Hengli Lu, Yiwei Zhang, et al.
Cancer Science (2024) Vol. 115, Iss. 10, pp. 3305-3319
Open Access | Times Cited: 2
Bayesian unsupervised clustering identifies clinically relevant osteosarcoma subtypes
Sergio Llaneza‐Lago, William D. Fraser, Darrell Green
Briefings in Bioinformatics (2024) Vol. 26, Iss. 1
Open Access | Times Cited: 2
Investigating Optimal Chemotherapy Options for Osteosarcoma Patients through a Mathematical Model
Trang Le, Sumeyye Su, Leili Shahriyari
Cells (2021) Vol. 10, Iss. 8, pp. 2009-2009
Open Access | Times Cited: 15
The hypoxia-related signature predicts prognosis, pyroptosis and drug sensitivity of osteosarcoma
Lin Hu, Xin Wu, Dongjie Chen, et al.
Frontiers in Cell and Developmental Biology (2022) Vol. 10
Open Access | Times Cited: 10
Impact of ABC Transporters in Osteosarcoma and Ewing’s Sarcoma: Which Are Involved in Chemoresistance and Which Are Not?
Massimo Serra, Claudia Maria Hattinger, Michela Pasello, et al.
Cells (2021) Vol. 10, Iss. 9, pp. 2461-2461
Open Access | Times Cited: 13
Natural killer cell-mimicking nanomaterial for overcoming the multidrug resistance of tumor via cascade catalysis
Minjie Li, Fan Gao, Qian‐Xiao Huang, et al.
Science China Materials (2022) Vol. 66, Iss. 3, pp. 1215-1226
Open Access | Times Cited: 9
Targeted alpha therapy with the 224Ra/212Pb-TCMC-TP-3 dual alpha solution in a multicellular tumor spheroid model of osteosarcoma
Anna Julie Kjøl Tornes, Vilde Yuli Stenberg, Roy H. Larsen, et al.
Frontiers in Medicine (2022) Vol. 9
Open Access | Times Cited: 9
Comprehensive analysis of hypoxia-related genes for prognosis value, immune status, and therapy in osteosarcoma patients
Tao Han, Zhouwei Wu, Zhe Zhang, et al.
Frontiers in Pharmacology (2023) Vol. 13
Open Access | Times Cited: 5
Development and Verification of a Hypoxic Gene Signature for Predicting Prognosis, Immune Microenvironment, and Chemosensitivity for Osteosarcoma
Fengfeng Wu, Juntao Xu, Mingchao Jin, et al.
Frontiers in Molecular Biosciences (2022) Vol. 8
Open Access | Times Cited: 8
A meta-analysis: the clinical value of PD-1 inhibitor or protein tyrosine kinase inhibitors in the treatment of advanced osteosarcoma
Binhao Shi, Junli Chang, Xingyuan Sun, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 4
Exploration of anti‑osteosarcoma activity of asiatic acid based on network pharmacology and in vitro experiments
He Pang, Hang Wu, Zeyu Zhan, et al.
Oncology Reports (2023) Vol. 51, Iss. 2
Open Access | Times Cited: 4
MgSiO3 Fiber Membrane Scaffold with Triggered Drug Delivery for Osteosarcoma Synergetic Therapy and Bone Regeneration
Junjie Mao, Jianqiang Bi, Zhenqian Sun, et al.
ACS Applied Materials & Interfaces (2024) Vol. 16, Iss. 27, pp. 34669-34683
Closed Access | Times Cited: 1

Scroll to top